Lipid peroxidation in diabetes mellitus.
暂无分享,去创建一个
[1] A. Ceriello,et al. Role of hyperglycemia in nitrotyrosine postprandial generation. , 2002, Diabetes care.
[2] G. Davı̀,et al. In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. , 1999, Circulation.
[3] H. Keen,et al. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. , 1985, The New England journal of medicine.
[4] G. Lutty,et al. Increased NADH oxidase activity in the retina of the BBZ/Wor diabetic rat. , 1998, Free radical biology & medicine.
[5] M. Sampson,et al. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. , 2002, Diabetes care.
[6] M. Laakso,et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. , 1998, The New England journal of medicine.
[7] B. Kemp,et al. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. , 2003, Diabetes.
[8] R. de Caterina,et al. Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F2-Isoprostane Formation in Hypercholesterolemic Subjects: No Further Effect of Vitamin E , 2002, Circulation.
[9] F. Cipollone,et al. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. , 2000, Cardiovascular research.
[10] M. Brownlee,et al. Negative consequences of glycation. , 2000, Metabolism: clinical and experimental.
[11] G. Zimmerman,et al. Peroxisome Proliferators Enhance Cyclooxygenase-2 Expression in Epithelial Cells* , 1999, The Journal of Biological Chemistry.
[12] E. Falleti,et al. Total Radical-Trapping Antioxidant Parameter in NIDDM Patients , 1997, Diabetes Care.
[13] M. Laakso,et al. Hyperglycemia and cardiovascular disease in type 2 diabetes. , 1999, Diabetes.
[14] G. FitzGerald,et al. Local Amplification of Platelet Function by 8-Epi Prostaglandin F2α Is Not Mediated by Thromboxane Receptor Isoforms* , 1996, The Journal of Biological Chemistry.
[15] A. Roussin,et al. Lack of concordance between plasma markers of cardiovascular risk and intima‐media thickness in patients with type 2 diabetes , 2004, Diabetes, obesity & metabolism.
[16] T. Nicotera,et al. Oxidative damage to DNA in diabetes mellitus , 1996, The Lancet.
[17] A. Gotto. Lipid management in diabetic patients: lessons from prevention trials. , 2002, The American journal of medicine.
[18] E. Feldman. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. , 2003, The Journal of clinical investigation.
[19] S. Wolff,et al. Protein glycation and oxidative stress in diabetes mellitus and ageing. , 1991, Free radical biology & medicine.
[20] A. Ceriello. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. , 2003, Diabetes care.
[21] M. Brownlee. Biochemistry and molecular cell biology of diabetic complications , 2001, Nature.
[22] J. Keaney,et al. Are ACE inhibitors a "magic bullet" against oxidative stress? , 2001, Circulation.
[23] J. Morrow,et al. F(2)-isoprostanes mediate high glucose-induced TGF-beta synthesis and glomerular proteinuria in experimental type I diabetes. , 2000, Kidney international.
[24] T. Lüscher,et al. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. , 1997, Circulation.
[25] B. Buckley,et al. Statins do more than just lower cholesterol , 1996, The Lancet.
[26] G. Davı̀,et al. Oxidative Stress and Platelet Activation in Homozygous Homocystinuria , 2001, Circulation.
[27] B. Shilton,et al. Role of fructose in glycation and cross-linking of proteins. , 1988, Biochemistry.
[28] Robert M. Anderson,et al. 5. Prevention or Delay of Type 2 Diabetes , 2016, Diabetes Care.
[29] K. Pritchard,et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[30] S. Tyagi,et al. Induction of oxidative stress by homocyst(e)ine impairs endothelial function * , 2001, Journal of cellular biochemistry.
[31] J P Cooke,et al. The endothelium: a new target for therapy , 2000, Vascular medicine.
[32] Robert M. Anderson,et al. Prevention or delay of type 2 diabetes. , 2004, Diabetes care.
[33] J. Watkins,et al. Diabetes, oxidative stress, and antioxidants: A review , 2003, Journal of biochemical and molecular toxicology.
[34] K. Shirai,et al. [Relationship between insulin resistance and oxidative stress in vivo]. , 2003, Journal of cardiology.
[35] Emma A. Meagherx. Treatment of atherosclerosis in the new millennium: is there a role for vitamin E? , 2003 .
[36] L. Geiss,et al. Estimated number of adults with prediabetes in the US in 2000: opportunities for prevention. , 2003, Diabetes care.
[37] P. Low,et al. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. , 2003, Diabetes.
[38] Joseph L Evans,et al. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. , 2002, Endocrine reviews.
[39] U. Laufs,et al. Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[40] J. Olzmann,et al. High glucose‐induced oxidative stress and mitochondrial dysfunction in neurons , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[41] H. Itoh,et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. , 1998, Hypertension.
[42] C. Kilo,et al. The role of cytosolic reductive stress in oxidant formation and diabetic complications. , 1999, Diabetes research and clinical practice.
[43] S. Apfel. Neurotrophic Factors and Diabetic Peripheral Neuropathy , 1999, European Neurology.
[44] A. Carrascosa,et al. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. , 2003, Free radical biology & medicine.
[45] S. Yusuf,et al. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. , 2002, Diabetes care.
[46] M. Levine,et al. A new recommended dietary allowance of vitamin C for healthy young women , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] G. Hobbs,et al. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.
[48] G. Davı̀,et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus , 2003, Journal of thrombosis and haemostasis : JTH.
[49] L. Ruilope,et al. Renoprotection and renin-angiotensin system blockade in diabetes mellitus. , 1997, American journal of hypertension.
[50] H. Westerhoff,et al. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta-cell failure? , 2000, Atherosclerosis.
[51] D. Betteridge,et al. Plasma 8‐epi‐PGF2α levels are elevated in individuals with non‐insulin dependent diabetes mellitus , 1995, FEBS letters.
[52] L S Geiss,et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. , 2001, Diabetes care.
[53] A. Coats. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20 536 high-risk individuals: a randomised placebo-controlled trial , 2002 .
[54] A. Flyvbjerg. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease , 2000, Diabetologia.
[55] Jian Zhang,et al. Hydrogen Peroxide Activates NFκB and the Interleukin-6 Promoter Through NFκB-Inducing Kinase , 2001 .
[56] C. Soto,et al. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis , 2000, Nature Network Boston.
[57] L. Tavazzi,et al. Antioxidant vitamins and prevention of cardiovascular disease: Epidemiological and clinical trial data , 2001, Lipids.
[58] M. Carrier,et al. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism , 2001, Diabetologia.
[59] D. Dixon,et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis , 2001, The Journal of cell biology.
[60] G. Davı̀,et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. , 1990, The New England journal of medicine.
[61] G. Davı̀,et al. Platelet activation in obese women: role of inflammation and oxidant stress. , 2002, JAMA.
[62] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.
[63] A. Koller,et al. PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes , 2004 .
[64] D. O'Connor,et al. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk , 2000, Journal of hypertension.
[65] M. Penn,et al. Lipoprotein Oxidation and Lipoprotein-lnduced Cell Injury in Diabetes , 1992, Diabetes.
[66] J. Loscalzo,et al. Diabetes, oxidative stress, and platelet activation. , 1999, Circulation.
[67] L. Aiello,et al. Role of vascular endothelial growth factor in diabetic vascular complications. , 2000, Kidney international. Supplement.
[68] B. Halliwell,et al. Reoxygenation injury and antioxidant protection: a tale of two paradoxes. , 1990, Archives of biochemistry and biophysics.
[69] S. Yagihashi,et al. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients , 2002, Diabetologia.
[70] J. Baynes,et al. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. , 1999, Diabetes.
[71] P. Tsao,et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. , 2001, Circulation research.
[72] R. Stocker,et al. The use of antioxidant supplements in coronary heart disease. , 2002, Atherosclerosis.
[73] I. Hirsch,et al. Reduced Plasma Peroxyl Radical Trapping Capacity and Increased Susceptibility of LDL to Oxidation In Poorly Controlled IDDM , 1994, Diabetes.
[74] S. Devaraj,et al. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. , 2001, Clinical chemistry.
[75] G. Davı̀,et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. , 1997, Circulation.
[76] U. Bayraktutan,et al. Free radicals, diabetes and endothelial dysfunction , 2002, Diabetes, obesity & metabolism.
[77] F. Santilli,et al. Enhanced Lipid Peroxidation and Platelet Activation in the Early Phase of Type 1 Diabetes Mellitus: Role of Interleukin-6 and Disease Duration , 2003, Circulation.
[78] G. Davı̀,et al. In Vivo Formation of 8-Epi-Prostaglandin F2α Is Increased in Hypercholesterolemia , 1997 .
[79] R. Mccarty,et al. Glycemic control of pain threshold in diabetic and control rats , 1990, Physiology & Behavior.
[80] J. Morrow,et al. The F2-isoprostane, 8-epi-prostaglandin F2 alpha, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. , 1992, Prostaglandins.
[81] S. Kahn,et al. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. , 1999, Diabetes.
[82] M. Roncaglioni,et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. , 2003, Diabetes care.
[83] Tonutti,et al. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non‐insulin‐dependent diabetic subjects , 1998, European journal of clinical investigation.
[84] J. Williamson,et al. Glucose and diabetic vascular disease 1 , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[85] E. Anggard,et al. F2-isoprostane evidence of oxidant stress in the insulin resistant, obese Zucker rat: effects of vitamin E. , 1999, European journal of pharmacology.
[86] Kathleen M. Fairfield,et al. Vitamins for chronic disease prevention in adults: scientific review. , 2002, JAMA.
[87] D. Sorescu,et al. NAD(P)H oxidase: role in cardiovascular biology and disease. , 2000, Circulation research.
[88] S. Robins. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? , 2003, Current opinion in lipidology.
[89] G. FitzGerald,et al. Oxidative stress and platelet activation in diabetes mellitus. , 1996, Diabetes research and clinical practice.